The Management of Patients with Epilepsy Taking Anti-epileptic Drugs Associated with Metabolic Bone Disease
Abstract number :
2.257
Submission category :
7. Anti-seizure Medications / 7D. Drug Side Effects
Year :
2022
Submission ID :
2204613
Source :
www.aesnet.org
Presentation date :
12/4/2022 12:00:00 PM
Published date :
Nov 22, 2022, 05:25 AM
Authors :
Brian Hanrahan, MD – St. Luke's University Health Network; Shreeja Kadakia, Resident – St. Luke's University Health Network; Ma Su Su Aung, Resident – St. Luke's University Health Network
Rationale: Several antiepileptic drugs (AEDs) are associated with osteoporosis or osteopenia with chronic use. However, there are no national guidelines on how to best manage patients on these AEDs. This study sought to evaluate the clinical management variability for patients with epilepsy that are at risk for AED-induced bone loss.
Methods: A retrospective chart review from August 1, 2020, to July 31, 2021, was completed for four epileptologists from St. Luke’s Neurology. A total of 377 patients aged 18 to 96 were prescribed one of the following AEDs known to affect bone health: carbamazepine, divalproex, phenobarbital, phenytoin, and primidone (Table 1). We collected age, sex, associated provider, AED, prophylactic measures used (vitamin D, calcium, bisphosphonates, multivitamin), the performance of DEXA scan, and DEXA results. Patients on one of these AEDs for a non-seizure-related ailment were excluded. Data was analyzed using a chi square test, a Cochran-Mantel-Haenszel test, and SPSS version 28 (Armonk, NY: IBM Corp) with p value < .05 denoting statistical significance.
Anti-seizure Medications